Patent · US Active

HDAC6 inhibitors, with improved solubility and their uses

US11198694B2 · kind B2 · utility

0Cited by

1References

14Claims

0Family size

Assignee

Universität Regensburg · DE

Inventors

Siavosh Mahboobi · Regensburg, DE
Herwig Pongratz · Regensburg, DE
Elisabeth Grünstein · Regensburg, DE

Key dates

Filing date	Jun 29, 2018
Grant date	Dec 14, 2021
Priority date	—
Expiry date	Jun 29, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to small molecule compounds and their use as HDAC inhibitors and their use in the treatment of various diseases, such as cancer. The present invention further relates to methods for improvement of solubility by introducing basic substituents which offer the opportunity to create pharmaceutically acceptable salts. Moreover, it comprises methods of synthesizing the compounds and methods of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.